CagriSema
Cagrilintide + Semaglutide
CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.
Mécanisme d'action
Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols use the combination in a single weekly injection. Phase 3 doses range from cagrilintide 2.4mg + semaglutide 2.4mg weekly.
Notes de recherche
Clinical Research Status
CagriSema is in Phase 3 trials (REDEFINE program) for obesity and type 2 diabetes, with regulatory submissions anticipated based on trial readouts. Phase 2 data demonstrated approximately 15.6% body weight loss at 32 weeks, numerically superior to semaglutide 2.4mg alone. The REDEFINE 1 Phase 3 trial reported up to 22.7% weight loss at 68 weeks, positioning it competitively against tirzepatide.
Key Published Findings
The dual amylin/GLP-1 approach produces additive weight loss beyond either mechanism alone, supporting the hypothesis that multi-receptor targeting enhances metabolic outcomes. Glycemic improvements were also observed, with potential for combined diabetes and obesity indications. The mechanistic rationale rests on amylin's distinct CNS satiety signaling through the area postrema complementing GLP-1's hypothalamic and gut-mediated effects.
Safety Profile
The adverse event profile combines elements of both components, with gastrointestinal effects (nausea, vomiting, diarrhea) being most common during dose escalation. Tolerability appears manageable with appropriate titration schedules, though direct comparisons to monotherapy discontinuation rates are still being evaluated. Injection site reactions are consistent with other subcutaneous peptide therapies.
Comparison to Related Compounds
CagriSema competes directly with tirzepatide (Mounjaro/Zepbound), which uses a single molecule targeting GIP and GLP-1 receptors simultaneously. The two-molecule approach allows independent dose optimization of each component but requires a single co-formulated injection. Weight loss magnitude appears comparable to tirzepatide's 20-25% in similar trial durations, though head-to-head data is needed for definitive comparison.
Community Observations
The obesity research community views CagriSema as Novo Nordisk's answer to tirzepatide's superior weight loss over semaglutide monotherapy. Clinicians note that the combination format may offer flexibility for patients who plateau on GLP-1 monotherapy. The amylin component is reported to address residual hunger that some patients experience even at maximum GLP-1 doses.
Moitié de vie
~7 days (combination)
Réconstitution
Pre-mixed formulation
Conservation
Lyophilisé
Refrigerate 2-8C.
Réconstitué
Refrigerate 2-8C. Use within 42 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que CagriSema ?
CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.
Comment agit CagriSema ?
Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.
Quel est le statut réglementaire de CagriSema aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de CagriSema ?
~7 days (combination)
Sous quels autres noms CagriSema est-il connu ?
Cagrilintide + Semaglutide
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète